ME00570A - Improved mycoplasma hyopneumoniae bacterin vaccine - Google Patents

Improved mycoplasma hyopneumoniae bacterin vaccine

Info

Publication number
ME00570A
ME00570A MEP-859/08A MEP85908A ME00570A ME 00570 A ME00570 A ME 00570A ME P85908 A MEP85908 A ME P85908A ME 00570 A ME00570 A ME 00570A
Authority
ME
Montenegro
Prior art keywords
mycoplasma hyopneumoniae
mixture
composition
provides
immunity
Prior art date
Application number
MEP-859/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Hsien-Jue Chu
Wumin Li
Zhichang Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME00570B publication Critical patent/ME00570B/me
Publication of ME00570A publication Critical patent/ME00570A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/825Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MEP-859/08A 2000-12-19 2001-12-11 Improved mycoplasma hyopneumoniae bacterin vaccine ME00570A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19
PCT/US2001/047865 WO2002049666A2 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Publications (2)

Publication Number Publication Date
ME00570B ME00570B (me) 2011-12-20
ME00570A true ME00570A (en) 2011-12-20

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-859/08A ME00570A (en) 2000-12-19 2001-12-11 Improved mycoplasma hyopneumoniae bacterin vaccine

Country Status (27)

Country Link
US (4) US20020131980A1 (xx)
EP (1) EP1343525B1 (xx)
JP (2) JP5074656B2 (xx)
KR (1) KR100874119B1 (xx)
CN (1) CN1296095C (xx)
AR (1) AR033410A1 (xx)
AT (1) ATE359813T1 (xx)
AU (2) AU2899302A (xx)
BG (1) BG66213B1 (xx)
BR (1) BRPI0116249B1 (xx)
CY (1) CY1106669T1 (xx)
CZ (1) CZ307075B6 (xx)
DE (1) DE60127994T2 (xx)
DK (1) DK1343525T3 (xx)
ES (1) ES2283452T3 (xx)
HR (1) HRP20030585B1 (xx)
HU (1) HU227431B1 (xx)
ME (1) ME00570A (xx)
MX (1) MXPA03005357A (xx)
MY (1) MY129765A (xx)
NZ (1) NZ526904A (xx)
PL (1) PL211174B1 (xx)
PT (1) PT1343525E (xx)
RS (1) RS51536B (xx)
TW (1) TWI308872B (xx)
WO (1) WO2002049666A2 (xx)
ZA (1) ZA200305545B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
BRPI0721083A2 (pt) 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed Tratamento de porcos com antígeno de pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN104043116A (zh) 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
JP5613061B2 (ja) 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Pcv2マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
NZ590010A (en) * 2008-06-25 2013-01-25 Braasch Biotech Llc Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
BRPI1010679B1 (pt) * 2009-05-19 2020-09-24 Bioproperties Pty Ltd Cepa de vacina de mycoplasma hyopneumoniae sensível à temperatura e aplicações da mesma, composiçao de vacina, método de preparaçao e uso da mesma
WO2010140377A1 (ja) 2009-06-04 2010-12-09 独立行政法人産業技術総合研究所 マイコプラズマ感染症用ワクチン
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
SG179037A1 (en) * 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
EP2563389B1 (en) 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
CN103623400B (zh) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
DK2938747T3 (da) 2012-12-28 2019-08-05 Boehringer Ingelheim Vetmedica Gmbh Fremgangsmåde til fremstilling af en mycoplasma vaccine
CN104338128B (zh) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
EP3454893A4 (en) * 2016-05-11 2020-01-01 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
BR112020011041A2 (pt) * 2017-12-04 2020-11-17 Intervet International B.V. vacina contra a doença de lyme canina
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
ZA881694B (en) 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
AU626271B2 (en) * 1987-11-03 1992-07-30 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5240706A (en) * 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
ATE160699T1 (de) 1990-05-29 1997-12-15 American Cyanamid Co Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
AU667858B2 (en) 1991-11-15 1996-04-18 Smithkline Beecham Corporation Gram-negative bacterial vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (ja) * 1993-11-19 2002-03-11 本田技研工業株式会社 キャニスタ
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
AU746442B2 (en) * 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
PT1474067E (pt) * 2001-07-02 2008-11-14 Pfizer Prod Inc Vacinação numa dose com mycoplasma hyopneumoniae
US20050220880A1 (en) * 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (it) * 2003-02-14 2004-08-15 Advance Holdings Ltd Sale di cetilpiridino di un agente antiinfiammatorio
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Also Published As

Publication number Publication date
HU227431B1 (en) 2011-06-28
MXPA03005357A (es) 2003-10-06
YU49303A (sh) 2006-08-17
US8187588B2 (en) 2012-05-29
BR0116249A (pt) 2004-03-02
NZ526904A (en) 2005-07-29
ES2283452T3 (es) 2007-11-01
AR033410A1 (es) 2003-12-17
KR100874119B1 (ko) 2008-12-15
PT1343525E (pt) 2007-07-12
ZA200305545B (en) 2004-10-18
KR20030065556A (ko) 2003-08-06
JP2009073855A (ja) 2009-04-09
AU2899302A (en) 2002-07-01
TWI308872B (en) 2009-04-21
US20070020296A1 (en) 2007-01-25
MY129765A (en) 2007-04-30
CZ20031721A3 (cs) 2004-04-14
BG107898A (bg) 2004-08-31
WO2002049666A2 (en) 2002-06-27
US9238065B2 (en) 2016-01-19
WO2002049666A3 (en) 2003-02-06
US20020131980A1 (en) 2002-09-19
US20120213816A1 (en) 2012-08-23
ME00570B (me) 2011-12-20
CN1489472A (zh) 2004-04-14
BG66213B1 (bg) 2012-05-31
HRP20030585A2 (en) 2005-06-30
JP2004518655A (ja) 2004-06-24
DE60127994D1 (de) 2007-05-31
CY1106669T1 (el) 2012-05-23
EP1343525A2 (en) 2003-09-17
JP5074656B2 (ja) 2012-11-14
DE60127994T2 (de) 2008-01-17
HUP0400687A3 (en) 2004-10-28
CN1296095C (zh) 2007-01-24
DK1343525T3 (da) 2007-06-04
AU2002228993B2 (en) 2006-06-29
CZ307075B6 (cs) 2018-01-03
RS51536B (sr) 2011-06-30
PL363220A1 (en) 2004-11-15
HUP0400687A2 (hu) 2004-06-28
PL211174B1 (pl) 2012-04-30
EP1343525B1 (en) 2007-04-18
HRP20030585B1 (en) 2008-03-31
US7666439B2 (en) 2010-02-23
ATE359813T1 (de) 2007-05-15
US20100119471A1 (en) 2010-05-13
HK1056513A1 (en) 2004-02-20
BRPI0116249B1 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
ME00569A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
ES2149361T3 (es) Vacuna viva modificada contra el brsv, mejorada.
Ivins et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
UA98812C2 (ru) Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
DE69333028D1 (de) Deletionsmutanten als impfstoffe gegen cholera
DE69527202D1 (de) Proteinartige adjuvantien
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
AU2001295673A1 (en) Vaccine composition
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
WO2021255690A3 (en) Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
EP1467771A4 (en) MYCOBACTERIAL VACCINE
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
BR0112792A (pt) Bacterina, preparação de vacina, e, métodos para proteger um suìno suscetìvel contra a colonização ou infecção de uma mycoplasma hyopneumoniae e para induzir uma resposta imune em um suìno suscetìvel contra a pneumonia micoplasmática causada por uma mycoplasma hyopneumoniae
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
TH60396A (th) Mycoplasma Hyopneumoniae แบคเทอรินวัคซีนที่ได้?รับการปรับปรุงให้ดีขึ้น
TH64293A (th) ไมโคพลาสมา ไฮโอนิวมอเนีย แบคทีรินวัคซีนที่ได้รับการปรับปรุง
TH62369A (th) วัคซีนมีชีวิตที่ไวต่ออุณหภูมิสำหรับ Mycoplasma hyopneumoniae